Paul Ruff to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Paul Ruff has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0,480
-
Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. PLoS One. 2024; 19(11):e0309778.
Score: 0,221
-
ASPECCT: panitumumab versus cetuximab for colorectal cancer--authors' reply. Lancet Oncol. 2014 Jul; 15(8):e303.
Score: 0,108
-
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014 May; 15(6):569-79.
Score: 0,106
-
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014 Jan; 50(2):320-31.
Score: 0,026
-
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009 Apr 02; 360(14):1408-17.
Score: 0,019